LEIDEN, The Netherlands, April 14, 2022 - MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode-PACT initiative that has been granted today an amount of €325 million by the Dutch National Growth Fund.
Oncode Institute will lead the Oncode-PACT consortium and its operations. With this investment, the consortium will develop cancer drug candidates faster and bring them to patients sooner. As a partner in Oncode-PACT, MIMETAS will develop the next generation of patient-specific cancer organoid models that include immune cells, blood vessels, and other essential cell types to drive novel cancer drug discovery and developm ent. Using these models, MIMETAS will screen compounds and targets using fully integrated, automatic phenotypic screening lines with AI data interpretation, bringing early validation and de-risking to the cancer drug development pipeline.